Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks

Login for users with Unibas email account...

Login for registered users without Unibas email account...

 
A comparative study of CSF neurofilament light and heavy chain protein in MS
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
 
ID 2832983
Author(s) Kuhle, J.; Plattner, K.; Bestwick, J. P.; Lindberg, R. L.; Ramagopalan, S. V.; Norgren, N.; Nissim, A.; Malaspina, A.; Leppert, D.; Giovannoni, G.; Kappos, L.
Author(s) at UniBasel Lindberg Gasser, Raija L.P.
Kappos, Ludwig
Year 2013
Title A comparative study of CSF neurofilament light and heavy chain protein in MS
Journal Multiple Sclerosis Journal
Volume 19
Number 12
Pages / Article-Number 1597-1603
Keywords Cerebrospinal fluid, multiple sclerosis, clinically isolated syndrome, neurodegeneration, neurofilament, neurofilament heavy chain, neurofilament light chain, relapse, disability, immunoassay, biomarker, study design
Abstract BACKGROUND: There is a lack of reliable biomarkers of axonal degeneration. Neurofilaments are promising candidates to fulfil this task. We compared two highly sensitive assays to measure two subunits of the neurofilament protein (neurofilament light (NfL) and neurofilament heavy chain (NfH)). METHODS: We evaluated the analytical and clinical performance of the UmanDiagnostics NF-light((R)) enzyme-linked immunosorbent assay (ELISA) in the cerebrospinal fluid (CSF) of a group of 148 patients with clinically isolated syndrome (CIS) or multiple sclerosis (MS), and 72 controls. We compared our results with referring levels of our previously-developed CSF NfH(SMI35) assay. RESULTS: Exposure to room temperature (up to 8 days) or repetitive thawing (up to 4 thaws) did not influence measurement of NfL concentrations. Values of NfL were higher in all disease stages of CIS/MS, in comparison to controls (p >/= 0.001). NfL levels correlated with the Expanded Disability Status Scale (EDSS) score in patients with relapsing disease (r(s) = 0.31; p = 0.002), spinal cord relapses and with CSF markers of acute inflammation. The ability of NfL to distinguish patients from controls was greater than that of NfH(SMI35) in both CIS patients (p = 0.001) and all MS stages grouped together (p = 0.035). CONCLUSIONS: NfL proved to be a stable protein, an important prerequisite for a reliable biomarker, and the NF-light((R)) ELISA performed better in discriminating patients from controls, compared with the ECL-NfH(SMI35) immunoassay. We confirmed and expanded upon previous findings regarding neurofilaments as quantitative markers of neurodegeneration. Our results further support the role of neurofilaments as a potential surrogate measure for neuroprotective treatment in MS studies.
Publisher SAGE
ISSN/ISBN 1352-4585 ; 1477-0970
edoc-URL http://edoc.unibas.ch/dok/A6338331
Full Text on edoc No
Digital Object Identifier DOI 10.1177/1352458513482374
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/23529999
ISI-Number WOS:000325696100010
Document type (ISI) Article
 
   

MCSS v5.8 PRO. 0.339 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
28/03/2024